

Figure 1









Figure 2**A ZIKV versus other flavivirus infections or vaccinations****B ZIKV versus healthy controls**

Figure 3**A Anti-Zika Virus IgM****B Anti-Zika Virus IgG****C Anti-Zika Virus IgM and IgG**

ZIKV patients (n=29)		Anti-ZIKV IgM		
Anti-ZIKV IgG		Positive	Borderline	Negative
	Positive	16	2	2
	Borderline	2	0	0
	Negative	6	0	1

Anti-ZIKV ELISA reactivity			
	IgM	IgG	IgM / IgG
n (positive/total)	24/29	20/29	28/29
Sensitivity	82.2%	69.0%	96.6%
95% CI	65.0-92.9%	50.6-82.9%	84.1-100%

D Time course analysis




Fig. 4





Fig. 5



১৩৫




Fig. 7





Fig. 8






Fig. 9A




Fig. 9B




Fig. 9C




Fig. 9D




Fig. 10A




Fig. 10B




Fig. 11A





Fig. 11B



Patient's anti-ZIKV IgM and IgG titer at day 5 and 41

Fig. 12